The future of physiologically based pharmacokinetic modeling to predict drug exposure in pregnant women

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 3, 2013, Pages

  Vinks, A A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; INDINAVIR; MIDAZOLAM; NIFEDIPINE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; HUMAN; MATERNAL HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; PHYSIOLOGY; PREDICTION; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SIMULATION; THIRD TRIMESTER PREGNANCY;

EID: 84881139783     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.9     Document Type: Review

References (10)

1. van Hasselt, J.G., Andrew, M.A., Hebert, M.F., Tarning, J., Vicini, P. & Mattison, D.R. The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics. Br. J. Clin. Pharmacol. 74, 932-939 (2012).
2. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
3. Abduljalil, K., Furness, P., Johnson, T.N., Rostami-Hodjegan, A. & Soltani, H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 51, 365-396 (2012).
4. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
5. Grillo, J.A. et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm. Drug Dispos. 33, 99-110 (2012).
6. Lu, G., Abduljalil, K., Jamei, M., Johnson, T.N., Soltani, H. & Rostami-Hodjegan, A. Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. Curr. Drug Metab. 13, 695-720 (2012).
7. Prevost, R.R., Akl, S.A., Whybrew, W.D. & Sibai, B.M. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 12, 174-177 (1992).
8. Ke, A.B., Nallani, S.C., Zhao, P., Rostami-Hodjegan, A. & Unadkat, J.D. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT: Pharmacometrics & Systems Pharmacology 1 (2012);e-pub ahead of print 26 September 2012.
9. Quinney S.K. et al. A semi-mechanistic metabolism model of CYP3A Substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology 1 (2012); e-pub ahead of print 26 September 2012.
10. Rowland M. Addressing drug development questions with physiologically based pharmacokinetics 2012. .